HOME > COMMENTARY
COMMENTARY
-
Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
-
Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
December 2, 2024
-
MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
Survey Hints LLP New Coverage Rule Could Push Generic Switches for Cancer Drugs, Pediatric Meds
October 8, 2024
-
LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
-
Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
-
How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
-
Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
July 12, 2024
-
Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
-
Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
June 4, 2024
-
Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
April 19, 2024
-
With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?
March 12, 2024
-
Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
-
Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
-
Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
-
Change of Tide in Reform: Lopsided Cost Cuts to Balanced Pro-Innovation Policy
December 27, 2023
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…